Amgen and Servier Collaborate Over Cardiovascular Disease (AMGN)

Amgen and Servier Collaborate Over Cardiovascular Disease (AMGN)


Biopharmaceutical company Amgen, Inc. (AMGN) announced on Tuesday that it has entered into an agreement to collaborate with Servier over cardiovascular disease.

The agreement will allow Amgen to work with Servier’s novel oral drug, which is currently used in the EU as Procoralan® for chronic heart failure. Amgen also received the right to develop and commercialize Servier’s investigational molecule, S38844. Servier now has rights to commercialize omecamtiv mecarbil in the EU.

Amgen will pay a $50 million payment to Servier for the use of ivabradine under the agreement.

Amgen shares were mostly flat during Tuesday morning trading. The stock is up 14% YTD.

The Bottom Line

Shares of Amgen, Inc. (AMGN) have a 1.90% yield based on Tuesday morning’s price of $98.92.

Amgen, Inc. (AMGN) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today